Problems and countermeasures of scientific research drug dispensing management in medical instisutions

Published on Jul. 08, 2026Total Views: 64 times Total Downloads: 18 times Download Mobile

Author: SHAO Xiyue ¹ LI Rongqi ² ZHOU Ziye ¹  ZHANG Xiuhua ¹

Affiliation: 1.Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325003, Zhejiang Province, China 2.Department of Pharmacy, Pingyang Affiliated Hospital of Wenzhou Medical University, Wenzhou 325400, Zhejiang Province, China

Keywords: Medical Institutions Basic research Clinical research Scientific drugs Dispensing and management Reflections

DOI: 10.12173/j.issn.2097-4922.202602042

Reference: SHAO Xiyue, LI Rongqi, ZHOU Ziye, ZHANG Xiuhua.Problems and countermeasures of scientific research drug dispensing management in medical instisutions[J]. Yaoxue QianYan Zazhi, 2026, 30(5): 1074 - 1080.DOI: 10.12173/j.issn.2097-4922.202602042[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

Given the increasing emphasis on the translation of clinical and basic research outcomes in medical institutions, numerous problems have emerged in the management of investigational drug dispensing related to such research. This study combined with existing regulations and years of experience in dispensing management, analyzes the current situation and proposes countermeasures. It first clarifies the scope of investigational drugs in medical institutions, including those used in basic research and clinical research. It analyzes the different scenarios and existing problems in the dispensing management of these two types of drugs. These issues may affect drug quality, lead to adverse events or drug loss, and in severe cases, compromise research quality, data authenticity, and the safety of study participants. The findings suggest that medical institutions should establish specific systems for the dispensing management of both basic and clinical research drugs, clarify responsible departments, standardize management processes, and regulate dispensing operations to reduce risks associated with the use of investigational drugs. Such measures will ensure precise and effective management and provide a reference for the scientific and standardized management of investigational drugs in medical institutions.

Full-text

Please download the PDF version to read the full text: download

References

1. 中华人民共和国药品管理法[S/OL]. (2019-08-27) [2025-04-23]. https://www.nmpa.gov.cn/xxgk/fgwj/flxzhfg/20190827083801685.html

2. 国家卫生健康委. 医疗卫生机构开展研究者发起的临床研究管理办法: 国卫科教发〔2024〕32号[EB/OL]. (2024-09-18) [2025-04-23]. https://www.nhc.gov.cn/qjjys/c100016/202409/3a3ad0a7b656420d9580b65f2321a623.shtml

3. 国家药品监督管理局, 国家卫生健康委. 国家药监局国家卫生健康委关于发布药物临床试验质量管理规范的公告(2020年第57号)[EB/OL]. (2020-04-26)[2025-04-23]. https://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20200426162401243.htmlNational

4. 山东省药学会. 药物临床试验用药品管理山东专家共识[J]. 山东大学学报(医学版), 2026, 64(4): 8-13.Shandong Pharmaceutical Association. Shandong Provincial expert consensus on investigational product management in drug clinical trials[J]. Journal of Shandong University (Health Sciences), 2026, 64(4): 8-13. DOI: 10.6040/j.issn.1671-7554.0.2025.1094.

5. EnglandE, DeakinCD, NolanJP, et al. Patient safety incidents and medication errors during a clinical trial: experience from a pre-hospital randomized controlled trial of emergency medication administration[J]. Eur J Clin Pharmacol, 2020, 76(10): 1355-1362. DOI: 10.1007/s00228-020-02887-z.

6. MéthotJ, BrissonD, GaudetD. On-site management of investigational products and drug delivery systems in conformity with Good Clinical Practices (GCPs)[J]. Clin Trials, 2012, 9(2): 265-271. DOI: 10.1177/1740774511431280.

7. TangY, FangX. Centralized daily drug management in clinical trial institutions and specific implementation plans[J]. Front Drug Saf Regul 2025, 5: 1620314. DOI: 10.3389/fdsfr.2025.1620314.

8. 孟睿, 李睿, 丁元杰, 等. 医疗卫生机构研究者发起的超说明书用药研究的管理探索与优化 [J]. 海南医学, 2025, 36(12): 1779-1783.MengR, LiR, DingYJ, et al. Exploration and optimization of the management of off-label drug use research initiated by researchers in medical and health institutions[J]. Hainan Medical Journal, 2025, 36(12): 1779-1783. DOI: 10.3969/j.issn.1003-6350.2025.12.021.

9. 程雅倩, 何文. 我国药物临床试验的开展和监管体系现状[J]. 中国药师, 2019, 22(6): 1132-1138.ChengYQ, HeW. Development status of clinical trials and supervising system in China [J]. China Pharmacist, 2019, 22(6): 1132-1138. DOI: 10.3969/j.issn.1008-049X.2019.06.039.

10. 普布扎西, 王萍. 研究者发起的临床研究法律规制——制度构建与合规审查要点[J/OL]. 中国医学伦理学, 1-13(2026-03-27). [PuBZX, WangP. Legal regulation of investigator-initiated clinical research-key points of institutional construction and compliance review[J/OL]. Chinese Medical Ethics: 1-13(2026-03-27).] https://kns.cnki.net/kcms2/article/abstract?v=yAka2kXFwSQxtPnCXn O_d4zXD59i30iOPqdAIR_N_Y-sSDDQxAPsFgi2BgZzIXRtkLRS AXXWTR1J26Dh40vUw7AHvZvxw5gxR3gqtsCAECblHGJMu0scR DGHCDbIxvTC27REiLQfQplSOuB0ajnZr2ZI7djXlIQ3nSD3_h6gu X2qbIsQMKSTow==&uniplatform=NZKPT&language=CHS.

11. 倪小清, 任智文, 宋玉洁, 等. 临床试验用药品的管理体系探索与实践[J]. 医药导报, 2025, 44(2): 336-341.NiXQ, RenZW, SongYJ, et al. Exploration and practice of the drug management systerm for clinical trials[J]. Herald of Medicine, 2025, 44(2): 336-341. DOI: 10.3870/j.issn.1004-0781.2025.02.028.

12. 刘金永, 李子玥. 药物临床试验过程中试验用药品管理的实践体会[J]. 中国药物评价, 2020, 37(5): 391-393.LiuJY, LiZY. Practical experience in the management of investigational product in clinical trials[J]. Chinese Journal of Drug Evaluation, 2020, 37(5): 391-393. DOI: 10.3969/j.issn.2095-3593.2020.05.016.

13. 韦芳, 邹萍. 临床试验用药品管理存在的问题分析[J]. 医药前沿, 2024, 14(18): 138-141.WeiF, ZouP. Analysis of problems in the management of investigational drugs in clinical trials [J]. Medical Frontier, 2024, 14(18): 138-141. DOI: 10.3969/j.issn.2095-1752.2024.18.044.

14. 徐佳琦. 医院药物临床试验中心药房的标准化建设和规范化管理[J]. 中国现代应用药学, 2019, 36(23): 2978-2982. [XuJQ. Standardized construction and management of clinical trial centralized pharmacy in the hospital[J]. Chinese Journal of Modern Applied Pharmacy, 2019, 36(23): 2978-2982.https://d.wanfangdata.com.cn/periodical/QKV20192020042800655326.